Novo Nordisk closes Dicerna acquisition deal
Novo Nordisk has completed the acquisition of Dicerna Pharmaceuticals, which is the Danish firm's biggest acquisition so far.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Novo Nordisk has closed the acquisition deal of Dicerna Pharmaceuticals, with which the Danish firm has collaborated to develop potential RNA drugs since 2019, Novo Nordisk announces in a press release on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
